Finding new molecular targets of Copper(II) complexes on triple negative breast cancer cells using mass spectrometry-based quantitative proteomics

LEON I.E

Congreso; Biosystems in Toxicology and Pharmacology- Current challenges. BTP 2022; 2022

One of the most aggressive classes of breast cancer is the Triple Negative Breast Cancer (TNBC) which accounts for approximately 15% of breast cancer cases and is associated with a poor prognosis since chemotherapy seems to be the only possible treatment, involving side effects. Metallo-drugs are a class of antitumor agents largelyused in the treatment of different kinds of solid tumors including breast, colon, and lung.Nevertheless, chemoresistance to platinum is one of the most relevant clinical problems in the treatment and has led to an innovative research approach focusing on the anticancer activity of non-platinum-based compounds. In this sense, copper complexes show promising antitumor, anti-angiogenic and anti-metastatic properties activity on vitro and in vivo studies. However, the study of activation pathways targeted by copper compounds has scarcely been reported in the literature, and so far, the data for the discovery of novel molecular targets in cancer have not been completely examined.Therefore, the goal of this work is to identify novel targets of two copper(II) complexes on MDA-MB-231 cells using Mass Spectrometry-based Quantitative Proteomics.The results showed that complex 1 up-regulated 14 proteins and complex 2 up-regulated 9 proteins among which stand out Heat shock proteins, sulforedoxin-1 and ADP-ATP traslocase 2. Besides, the complexes 1 and 2 down-regulated 23 and 22 proteins, respectively. DNA replications factors and tumor suppressor genes factors appear as the most relevant down-regulated proteins.